New Product Launch
Osteothrombosis is the leading cause of death and accounts for 52% of deaths worldwide. In Pakistan more than 120,000 people die of cardiac diseases every year. The role of antithrombotics has always remained pivotal in curbing the manifestations of CVD. Getz Pharma is proud to introduce the first prasugrel of Pakistan “Prisa”. It is the latest antiplatelet approved by FDA for the management of patients with Acute Coronary Syndrome.
Dec 2011 marked a new milestone for Getz Pharma as the first penicillin product of Getz Pharma; Amclav was launched in Pakistan. Amclav is the first penicillin product manufactured at the new state of the art penicillin manufacturing facility.
Amclav is a broad spectrum bactericidal antibiotic - the combination of Amoxicillin and Clavulanic acid indicated for the treatment of major upper and lower respiratory tract infections and also for infections of the skin and urinary tract. Amclav is available in full tablet range- 375 mg, 625 mg & 1 gm and also as Amclav suspension in 156.25 mg/5 ml, Amclav DS 312.5 mg/5 ml and Amclav Plus 457 mg/5ml.
Diora (Diacerein) is an anthraquinone derivative that is used in osteoarthritis. It acts via inhibition of interleukin-1b. Diacerein having properties such as anti-inflammatory analgesics with structure modifying effect in osteoarthritis is designed especially for the treatment of osteoarthritis. It was launched in November 2011.
Diora (Diacerein) was launched in the market of Musculoskeletal products, used for the treatment of arthritis. Furthermore, the addition of Diora has also resulted in enrichment of Getz Pharma’s orthopedics portfolio.
Diora is marketed as the first Disease Modifying Osteoarthritis Drug which reduces the progression of Osteoarthritis. Diacerein has a unique mode of action that distinguishes it from other drugs used in OA, such as NSAIDs or corticosteroids. Diacerein has been shown as potent inhibitor of the production and activity of IL-1 and other catabolic cytokines expressed in OA.
Basagine (Insulin Glargine):
Basagine (Insulin Glargine) is a long acting insulin analogue, launched in September 2011.
At the time of its launch, only one Insulin Glargine was available in Pakistan’s pharma industry. The major challenge with regard to entering this market was to strengthen the position of Getz Pharma in Cardio Metabolic portfolio and launch another biotech molecule after Insuget and Unipeg.
The launch of Basagine has further enhanced the image of Getz Pharma as an innovative company focusing on the introduction of therapeutic advancements to compliment our commitment towards the community. Basagine is also a depiction of Getz Pharma’s heritage of successful establishment of new concepts through academic promotion, dissemination of scientific information and latest updates among the healthcare community.
Getofin (Ceftriaxone) is the third generation injectable cephalosporin indicated for infections of respiratory tract, urinary tract, reproductive organs and skin. It is also prescribed as prophylaxis in surgeries, for meningitis and typhoid. It was launched in July 2011.
The anti-infective market is the most promising market of Pharma industry, growing at a fast pace. It is now overcrowded with a number of players.
The launch of Getofin resulted in enrichment of Getz Pharma’s antibiotic portfolio.
Febuxostat is a new orally administered nonpurine inhibitor of xanthine oxidase. Getz Pharma launched Zurig in Pakistan on 4th May, 2011.
Febuxostat has been studied and evaluated in multiple clinical trials involving more than 4,000 subjects, in some for up to five years. These trials demonstrated Febuxostat superiority to Allopurinol at achieving serum uric acid levels of less than 6.0 mg/dL.
Febuxostat has an established safety profile with no dose adjustments in patients with mild-to-moderate renal impairment, a condition often associated with patients who have hyperuricemia and gout.
Zurig (Febuxostat) is a once-daily oral medication, available as 40mg and 80mg tablets in a pack size of 20’s.
At present, diabetes has affected more than 320 million people all over the word and is the leading cause of blindness, renal failure, cardiovascular and cerebrovascular diseases. This alarming cause may call for the instant, better and effective management of diabetes.
Trevia (Sitagliptin) is indicated mainly for the management of Type-2 Diabetes Mellitus was launched in 22nd Feb 2011. At that time, the market had only four players including Getz Pharma but now we are competing with a number of players.
As part of our marketing strategy, we launched a campaign based on the authentic international body recognition to the molecule in the entire Gliptins market. The tag line of the campaign was “The first FDA approved DPP-4 inhibitor”. This campaign enforced the safe use of the drug for the management of Type-2 diabetes Mellitus and included posters, presentations and foreign speaker sessions.
Trevia has now become one of the largest brands in the market. This remarkable success would not have been possible without the hard work, constant effort and passion of our colleagues and field force and by the trust shown in our product by the doctors and consumers.
Amtas (Amlodipine + Telmisartan):
Amtas is a very healthy addition to the Getz Cardio metabolic portfolio which already has innovative brands like Tasmi, Co-Tasmi , Advant, Nebil, Prisa, Lipiget & Rovista.
Amtas is a once daily, single pill combination of the angiotensin receptor blocker (ARB) telmisartan, and the calcium channel blocker (CCB) amlodipine.
Indicated in hypertension alone or in combination with other antihypertensive agents.
Solifen (Solifenacin succinate):
Solifen-a selective M3 receptor antagonist & first solifenacin succinate of Pakistan was launched on 17th June, 2010 with great passion, dedication and aggression. This has been the second mega launch in Urology segment after the memorable and remarkable launch of Tamsolin, the first Tamsulosin HCl- a selective alpha-1 blocker. Dr. Salman-El-Khalid, Consultant Urologist, Urology department - Kidney Centre Karachi, was the key note speaker. He enlightened the audience on the prevalence and management of the disease. The condition is very common in both sexes but more pronounced in females, since there is very little awareness about the disease.
Solifen is indicated for OAB-over active bladder, a disease condition characterized by urgency (strong urge to urinate), frequency (frequent toilet trips) and incontinence (involuntary leakage of urine). All notable urologists across Pakistan welcomed the launch of Solifen and recommended that this molecule was the need of the hour to effectively manage the ever increasing cases of overactive bladder.
Solifen is now a market leader in OAB market segment.
[Archived News Articles]